Bothell, Wash.
Went public 03/07/01 at $7 per share
Filing Range: 7.0 million shares at $8 to $10
Offering Size: $63 million
Post Offering Valuation: $206.78 million
Shares Outstanding: 29.1 million shares
Underwriters: J.P. Morgan Chase & Co./CIBC World Markets/ Banc of America Securities LLC
Company Counsel: Venture Law Group
Manager Counsel: Cahill Gordon & Reindel
Auditor: Pricewaterhouse Coopers LLP
The Company:
Develops monoclonal antibody-based cancer therapeutics. The company specializes in testing a treatment for tumors associated with breast, prostate, lung, ovarian and colon cancers as well as completing animal trials on cancers of the blood.
Venture Backers:
Sofinnova Ventures
BA Venture Partners
OVP Venture Partners
Indosuez Ventures
Financing Rounds:
Number of Round Amt.
Round # Round Date Stage Investors ($ thousands)
1 01/01/1998 2 Early Stage 7250.0
2 04/01/1998 2 Early Stage 6750.0
3 12/22/1999 3 Expansion 32000.0
Financials:
(Data in $ millions except EPS)
Y/E
(12/31/00)
Total Revenues: $0.09
Net Income: (7.8)
EPS: ($2.54)